drugset

drugset / Trial / NCT02154087

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

NCT02154087 ↗

Phase 2 Terminated 1 enrolled Healthpoint

NaSingle-groupOpen-labelTreatment

Summary

Assess the influence of HP802-247 on biochemical and cellular markers of inflammation in chronic venous leg ulcers

Timeline

Start: 2014-07
Primary completion: 2015-07
Completion: 2015-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HP802-247	Cell therapy	0.26 ml	Other

Indications